Skip to main content
DGX
NYSE Industrial Applications And Services

Quest Diagnostics Appoints Former Walgreens Boots Alliance CEO Timothy Wentworth to Board

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
7
Price
$200.88
Mkt Cap
$22.07B
52W Low
$157.2
52W High
$213.5
Market data snapshot near publication time

summarizeSummary

Quest Diagnostics has appointed Timothy Wentworth, former CEO of Walgreens Boots Alliance and other major healthcare firms, as an independent director, bringing significant industry and leadership experience to the board.


check_boxKey Events

  • New Independent Director Appointed

    Timothy Wentworth, former CEO of Walgreens Boots Alliance, Evernorth Health Services, and Express Scripts, has been elected to the Board of Directors, effective March 9, 2026.

  • Strengthens Board Expertise

    Mr. Wentworth brings extensive leadership experience in large, publicly traded healthcare organizations, with expertise in health plan, employer, and consumer channels, enhancing the board's strategic capabilities.

  • Committee Appointments

    He will serve on the Board's Compensation and Leadership Development Committee and the Quality and Compliance Committee.

  • Standard Director Compensation

    As part of his compensation, Mr. Wentworth received a prorated one-time grant of restricted share units valued at approximately $43,000.


auto_awesomeAnalysis

The appointment of Timothy Wentworth, a seasoned leader with extensive CEO experience from major healthcare organizations like Walgreens Boots Alliance and Evernorth Health Services, significantly strengthens Quest Diagnostics' Board of Directors. His deep expertise in health plan, employer, and consumer channels, along with operational and HR knowledge, is highly relevant to the company's strategic direction and will enhance governance and oversight.

At the time of this filing, DGX was trading at $200.88 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $22.1B. The 52-week trading range was $157.20 to $213.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed DGX - Latest Insights

DGX
Apr 27, 2026, 4:17 PM EDT
Filing Type: FWP
Importance Score:
7
DGX
Apr 21, 2026, 6:48 AM EDT
Filing Type: 8-K
Importance Score:
7
DGX
Apr 21, 2026, 6:47 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
DGX
Mar 12, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
DGX
Feb 26, 2026, 4:38 PM EST
Filing Type: 10-K
Importance Score:
8
DGX
Feb 10, 2026, 6:53 AM EST
Filing Type: 8-K
Importance Score:
8
DGX
Jan 12, 2026, 4:37 PM EST
Filing Type: 8-K
Importance Score:
7